anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cardiometabolic disorders, such as obesity, insulin resistance, and hypertension, prior to and within pregnancy are increasing in prevalence worldwide. Pregnancy-associated cardiometabolic disease poses a great risk to the short- and long-term well-being of the mother and offspring. Hypertensive pregnancy, notably preeclampsia, as well as gestational diabetes are the major diseases of pregnancy growing in prevalence as a result of growing cardiometabolic disease prevalence. The mechanisms whereby obesity, diabetes, and other comorbidities lead to preeclampsia and gestational diabetes are incompletely understood and continually evolving in the literature. In addition, novel therapeutic avenues are currently being explored in these patients to offset cardiometabolic-induced adverse pregnancy outcomes in preeclamptic and gestational diabetes pregnancies. In this review, we discuss the emerging pathophysiological mechanisms of preeclampsia and gestational diabetes in the context of cardiometabolic risk as well as the most recent preclinical and clinical updates in the pathogenesis and treatment of these conditions.
Formulations for transdermal pharmaceutical compositions including a synergistic combination of low doses of testosterone with a selective estrogen receptor modulator (C-SERM) that are combined with transdermal permeation enhancers are disclosed. Transdermal pharmaceutical compositions can be designed with various release rates, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Transdermal pharmaceutical compositions include liquid dosage forms, such as, for example solutions, liquid sprays, lotions, and the like. Additionally, transdermal pharmaceutical compositions include semi-solid dosage forms, such as, for example emulsions, creams, gels, pastes, ointments, and the like. Transdermal pharmaceutical compositions will deliver testosterone and C-SERM through the skin and directly into the patient's bloodstream, thereby providing high bioavailability of testosterone and C-SERM. The dosage regimen of the transdermal pharmaceutical compositions can be easily tailored for individual patients according to the baseline blood levels of testosterone and estradiol.
Recombining plasmid (A), allowing transformation of a bacterial host and its use as a cloning vector, comprises (a) a regulon (R) homologous to the bacterial host in its non-transformed state, and (b) in 'reading phase' with R an inserted DNA which codes for the amino-acid sequence of a heterologous polypeptide (I). Bacteria transformed with (A) can express this amino-acid sequence in a recoverable form. Also claimed are the plasmids, cloning vectors, transformed bacterial cultures and polydeoxyribonucleotides consisting of the codons for (I). Used esp. where (I) is a mammalian hormone or intermediate e.g. human pre-pro- or pro-insulin; insulin chains A or B; luteinising hormone; human or bovine growth hormones; ACTH; pancreatic polypeptide or somatostatin. Immunogenic substance contg. polypeptide haptens can also be produced.
Patients will undergo surveillance according to current Danish Guidelines with CT-scans at months 12 and 36 postoperative and colonoscopy every 5 year until age 75. Longitudinal blood samples will be collected at same time-points as in the experimental group but not analyzed until end of trial. At baseline and months 12, 18, 24 and 36 patients complete the QoL questionnaires including EORTC QLQ-C30, fear of cancer recurrence inventory (FCRI), and impact of events scale for cancer (IES-C).
Patients receive TLR8 agonist VTX-2337 SC on days 3, 10, and 17 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 or TLR8 agonist VTX-2337 SC on days 1, 8, and 15 and paclitaxel IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PURPOSE:To provide a novel compound having powerful hair growing activity. CONSTITUTION:The objective compound of the formula. This compound can be produced by conventional oxidation of n-pentadecanol nicotinate using an oxidizing agent. This compound has more powerful hair growing activity than those for odd-numbered chain aliphatic alcohol esters having been reported as having hair growing activity or the above-mentioned n-pentadecanol nicotinate having powerful hair growing activity, therefore, being useful as an active ingredient for hair growers. The other objective hair grower can be produced by conventionally mixing the above active ingredient with one of various kinds of base such as milky lotion, cream, lotion, or hair tonic. The concentration of this active ingredient in the above preparations is suitably 0.1-10wt.% or so.
Within 4 weeks before uvulopalatopharyngoplasty, patients are invited for this study. After written informed consent gained, the eligibilities are checked. Eligible patients are arrogated into experimental or control group randomly prior to surgery. Experimental group receives the DS administration at least 12 hours before surgery. During peri-operative period, pain management are conducted following our routine practice. Pain intensity, consumption of analgesics, adverse events, swallow function and life quality are all assessed and recorded within 14 days after surgery.
Study participants will receive 20 minutes of PEMFs (10 minutes per leg) on a weekly basis for 16 weeks (Week 1-16). Participants would not be aware of treatment/ sham allocation, as the PEMF device is indistinguishable in operational and non-operational modes. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
People included in this group will be assigned to a standard physical activity program that will follow the guidelines of the American College of Sport and Medicine. The program will include moderate intensity aerobic and strength training, three times a week for a total amunt of 200 min of physical activity/week.
The participants in this group will not receive the TranS-C treatment but will have access to usual care based on their needs and preferences, including but not limited to pharmacological interventions, psychological interventions, and complementary and alternative medicine. A treatment tracking log will be used to monitor the care the participants receive during the study period. The CAU group will receive self-help TranS-C materials after completing all of the assessments. We will monitor the participants' weekly depression severity using PHQ-9 and refer those who have serious suicidal risk to the PI for further assessment and professional mental health services if deemed necessary.
Updated analyses were conducted at a median follow-up of 62 months. In the Femara arm, 71% of the patients were treated for a least 3 years and 58% of patients completed at least 4.5 years of extended adjuvant treatment. After the unblinding of the study at a median follow-up of 28 months, approximately 60% of the selected patients in the placebo arm opted to switch to Femara. 

In this updated analysis shown in Table 9, Femara significantly reduced the risk of breast cancer recurrence or contralateral breast cancer compared with placebo (HR 0.75; 95% CI 0.63, 0.89; P=0.001). However, in the updated DFS analysis (interval between randomization and earliest event of loco-regional recurrence, distant metastasis, contralateral breast cancer, or death from any cause) the treatment difference was heavily diluted by 60% of the patients in the placebo arm switching to Femara and accounting for 64% of the total placebo patient- years of follow-up. Ignoring these switches, the risk of DFS event was reduced by a non-significant 11% (HR 0.89; 95% CI 0.77, 1.03). There was no significant difference in distant disease-free survival or overall survival.
BACKGROUND AND AIMS: The importance of withdrawal time during colonoscopy cannot be overstated in mitigating the risk of missed lesions and postcolonoscopy colorectal cancer. We evaluated a novel colonoscopy quality metric called the effective withdrawal time (EWT), which is an artificial intelligence (AI)-derived quantitative measure of quality withdrawal time, and its association with various colonic lesion detection rates as compared with standard withdrawal time (SWT).
METHODS: Three hundred fifty video recordings of colonoscopy withdrawal (from the cecum to the anus) were assessed by the new AI model. The primary outcome was adenoma detection rate (ADR) according to different quintiles of EWT. Multivariate logistic regression, adjusting for baseline covariates, was used to determine the adjusted odd ratios (ORs) for EWT on lesion detection rates, with the lowest quintile as reference. The area under the receiver-operating characteristic curve of EWT was compared with SWT.
RESULTS: The crude ADR in different quintiles of EWT, from lowest to highest, was 10.0%, 31.4%, 33.3%, 53.5%, and 85.7%. The ORs of detecting adenomas and polyps were significantly higher in all top 4 quintiles when compared with the lowest quintile. Each minute increase in EWT was associated with a 49% increase in ADR (aOR, 1.49; 95% confidence interval [CI], 1.36-1.65). The area under the receiver-operating characteristic curve of EWT was also significantly higher than SWT on adenoma detection (.80 [95% CI, .75-.84] vs .70 [95% CI, .64-.74], P < .01).
CONCLUSIONS: AI-derived monitoring of EWT is a promising novel quality indicator for colonoscopy, which is more associated with ADR than SWT.
The utility model discloses small equipment capable of immediately manufacturing cosmetics. The small equipment capable of immediately manufacturing the cosmetics comprises a box body, a sun lamp, an ultraviolet radiator lamp, an operating platform, a glass trapdoor, a cosmetics manufacturing machine and a quality detecting device, the sun lamp and the ultraviolet radiator lamp are arranged at the upper end of the box body, the operating platform is arranged inside the end of the box body, the glass trapdoor is arranged at the front end of the operating platform, the cosmetics manufacturing platform is arranged at the upper end of the operating platform, and the quality detecting device is arranged on one side of the cosmetics manufacturing machine, air permeable equipment is arranged at the rear end of the box body, and also a filter is arranged between the air permeable equipment and the operating platform. In manufacturing, the ultraviolet radiator lamp and the air permeable equipment are opened so as to disinfect and ventilate the inner end of the small equipment capable of immediately manufacturing the cosmetics. For air smoke which is produced in the manufacturing process, an adverse switch can be opened so that the air permeable equipment can rotate reversely, and then the air smoke is drained through the filter. After being finished, the cosmetics is filled into the quality detecting device and detected in quality, random implementation is conducted, and manpower is saved. Meanwhile, the cosmetics which are suitable for people can be manufactured according to demands of the people. The small equipment capable of immediately manufacturing the cosmetic is simple to operate and convenient to use.
Fluticasone Propionate and Salmeterol HFA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma. Fluticasone propionate and salmeterol HFA has not been studied in subjects with acutely deteriorating asthma. The initiation of Fluticasone Propionate and Salmeterol HFA in this setting is not appropriate.

Serious acute respiratory events, including fatalities, have been reported when salmeterol, a component of Fluticasone Propionate and Salmeterol HFA, has been initiated in patients with significantly worsening or acutely deteriorating asthma. In most cases, these have occurred in patients with severe asthma (e.g., patients with a history of corticosteroid dependence, low pulmonary function, intubation, mechanical ventilation, frequent hospitalizations, previous life-threatening acute asthma exacerbations) and in some patients with acutely deteriorating asthma (e.g., patients with significantly increasing symptoms; increasing need for inhaled, short-acting beta2-agonists; decreasing response to usual medications; increasing need for systemic corticosteroids; recent emergency room visits; deteriorating lung function). However, these events have occurred in a few patients with less severe asthma as well. It was not possible from these reports to determine whether salmeterol contributed to these events.

Increasing use of inhaled, short-acting beta2-agonists is a marker of deteriorating asthma. In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate and Salmeterol HFA with a higher strength, adding additional ICS, or initiating systemic corticosteroids. Patients should not use more than 2 inhalations twice daily of Fluticasone Propionate and Salmeterol HFA.

Fluticasone Propionate and Salmeterol HFA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Fluticasone propionate and salmeterol HFA has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.

When beginning treatment with Fluticasone Propionate and Salmeterol HFA, patients who have been taking oral or inhaled, short-acting beta2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.
PURPOSE OF REVIEW: As research on the potential impact of nutrition on mental disorders, a significant component of global disability continues to grow the concepts of "nutritional psychiatry, psycho-dietetics/nutripsychiatry" have taken their place in the literature. This review is a comprehensive examination of the literature on the the potential mechanisms between common mental disorders and nutrition and evaluates the effectiveness of dietary interventions.
RECENT FINDINGS: Inflammation, oxidative stress, intestinal microbiota, mitochondrial dysfunction, and neural plasticity are shown as potential mechanisms in the relationship between mental disorders and nutrition. As a matter of fact, neurotrophic factors, which make important contributions to repair mechanisms throughout life, and neuronal plasticity, which plays a role in mental disorders, are affected by nutritional factors. In metabolism, the antioxidant defense system works with nutritional cofactors and phytochemicals. A balanced, planned diet that provides these components is more likely to provide nutrients that increase resilience against the pathogenesis of mental disorders. Nutrition can be considered a risk factor for mental disorders. Therefore, developing public health strategies focused on improving diet may help reduce the global burden of mental disorders and other related diseases.
Several advanced imaging techniques are now available for endoscopists managing inflammatory bowel disease (IBD) patients. These tools, including dye-based and virtual chromoendoscopy, probe-based confocal laser endomicroscopy and endocytoscopy, are increasingly innovative applications in clinical practice. They allow for a more in-depth and refined evaluation of the mucosal and vascular bowel surface, getting closer to histology. They have demonstrated a remarkable ability in assessing intestinal inflammation, histologic remission, and predicting relapse and favorable long-term outcomes. In addition, the future application of molecular endoscopy to predict biological drug responses has yielded preliminary but encouraging results. Furthermore, these techniques are crucial in detecting and characterizing IBD-related dysplasia, assisting endoscopic mucosal resection and submucosal dissection towards a surgery-sparing approach. Artificial intelligence (AI) holds great potential in this promising landscape, as it can provide an objective and reproducible assessment of inflammation and dysplasia. Moreover, it can improve the prediction of outcomes and aid in subsequent therapeutic decision-making. This review aims to summarize the promising role of state-of-the-art advanced endoscopic techniques and related AI-enabled models for managing IBD, paving the way for precision medicine.
UNLABELLED: Chromoplexy is a phenomenon defined by large-scale chromosomal chained rearrangements. A previous study observed chromoplectic events in a subset of Ewing sarcomas (ES), which was linked to an increased relapse rate. Chromoplexy analysis could potentially facilitate patient risk stratification, particularly if it could be detected with clinically applied targeted next-generation sequencing (NGS) panels. Using DELLY, a structural variant (SV) calling algorithm that is part of the MSK-IMPACT pipeline, we characterized the spectrum of SVs in EWSR1-fused round cell sarcomas, including 173 ES and 104 desmoplastic small round cell tumors (DSRCT), to detect chromoplexy and evaluate its association with clinical and genomic features. Chromoplectic events were detected in 31% of the ES cases and 19% of the DSRCT cases. EWSR1 involvement accounted for 76% to 93% of these events, being rearranged with diverse noncanonical gene partners across the genome, involving mainly translocations but also intrachromosomal deletions and inversions. A major breakpoint cluster was located on EWSR1 exons 8-13. In a subset of cases, the SVs disrupted adjacent loci, forming deletion bridges. Longitudinal sequencing and breakpoint allele fraction analysis showed that chromoplexy is an early event that remains detectable throughout disease progression and likely develops simultaneously with the driver fusion. The presence of chromoplexy was validated in an external ES patient cohort with whole exome sequencing. Chromoplexy was significantly more likely to be present in cases that were metastatic at presentation. Together, this study identifies chromoplexy as a frequent genomic alteration in diverse EWSR1-rearranged tumors that can be captured by targeted NGS panels.
SIGNIFICANCE: Chromoplexy is detectable using targeted NGS in a substantial portion of EWSR1-rearranged round cell sarcomas as an early and persistent clonal event, expanding the genomic complexity of fusion-associated sarcomas.
An object of the invention is an antineoplastic composition which contains biologically active substances such as ethyl carbamate and salts and finds application in the treatment of malignant tumour diseases, bone diseases, multiple sclerosis and has both analgesic and cytophylactic effect. The antineoplastic composition contains by weight. vol. %: ethyl carbamate from 1 to 3, ethylene glycol from 0.97 to 0.99, methyl 4-hydroxybenzoate from 0.01 to 0.02, salts from the group of magnesium chloride, copper acetate, sodium bicarbonate, sodium persulfate and chloral hydrate from 0.03 to 3.30, a pharmaceutically acceptable carrier to 100. Optionally it also contains triethylene melamine in an amount of 0.0029 to 0.003 wt. % .
The invention relates to a construction method for generating a special disease broad table in the medical field, which belongs to the technical field of special disease data systems and comprises the following operation steps: the first step: and setting up Debezium, kafka an environment. And a second step of: subscribing change data in real time, capturing data change logs of each business sub-table. And a third step of: debezium establish a connection with a database. Fourth step: debezium deliver the collected data to the corresponding Kafka message component. Fifth step: creating a Topic-message theme, setting a partition and a copy based on each business sub-table, and sequentially sending. Sixth step: and configuring an acquisition task to generate a disease-specific large-width table. Seventh step: and after the full-quantity information synchronization is completed, synchronously supplementing the increment information. Eighth step: and writing the final result value into a wide table field in the target library to form a disease-specific wide table. Ninth step: the data for the patient-specific portrayal is integrated into a broad table. Has the advantages of convenient operation, high efficiency and good stability. The integrity and the accuracy of patient specific disease data acquisition are improved.
Embodiments described herein provide for a healthcare ecosystem of computing devices participating as nodes of a distributed ledger (e.g., blockchain). The distributed ledger includes NFTs representing corresponding patients, where the initial NET behaves logically as a token scaffold that represents a "digital twin" of the particular patient. The initial patient token represents personal profile data of patient personal data for the patient. The nodes may generate new data and/or new sub-tokens (or other blockchain entry type) representing new data, which the nodes associate with the token scaffold. The sub-tokens contain data for representing physical or digital specimens, health data, and data derived from the health data (e.g., cell lines, organoids, other model systems). As the nodes generate and associate new sub-tokens to the patient's token scaffold over time, the token scaffold graphs and facilitates integration of patient-specific data and evolves into a robust electronic health record (EHR) and digital twin.
The invention relates to a solvent used for treating Parkinson's disease. The invention belongs to the technical field of Chinese and Western medicine combined preparation. The solvent is mainly composed of 10 traditional Chinese medicines such as tall gastrodia rhizome, sharpleaf uncaria stem with hooks, salvia miltiorrhiza, Chinese quince, scorpion, lumbricus, and red berry jackinthepulpit tuber; 2 Western medicines such as musk injection and levodopa injection; and an auxiliary material which is distillate spirit. The ratio of the traditional Chinese medicine to the Western medicine to the auxiliary material is 1.2-0.5:1. The medicine liquid is an external solvent, and provides functions such as meridian dredging, wind subduing, qi benefiting, blood nourishing, refreshing, resuscitation, blood circulation activating, phlegm expelling, dopamine receptors direct exciting, and dopamine release promoting. The solvent has good treatment against Parkinson's disease, and caused no toxic or side effect. Therefore, a novel approach for treating Parkinson's disease is developed.
Recurrent urinary tract infections (rUTIs) are common and can significantly impact a patient's quality of life. The mainstay of treatment is antibiotic-based, which contributes to the global problem of antibiotic resistance among urinary pathogens, so many alternative therapies have been explored. In this mini-review we evaluate evidence for intravesical agents that prevent rUTI, including antibiotic and nonantibiotic options. The current evidence supports the use of intravesical agents that replenish the glycosaminoglycan layer and of aminoglycoside antibiotics as safe and effective therapies to prevent rUTI. PATIENT SUMMARY: We reviewed evidence on the use of bladder instillations to treat repeated urinary infections. Studies have shown that agents that improve the bladder surface and one specific antibiotic class are effective and safe treatments for prevention of recurrent infections.